1. Oncologic Outcomes of Incidental Versus Biopsy-diagnosed Grade Group 1 Prostate Cancer: A Multi-institutional Study
- Author
-
Riccardo Leni, Emily A. Vertosick, Roderick C.N. van den Bergh, Timo F.W. Soeterik, Joris G. Heetman, Harm H.E. van Melick, Marco Roscigno, Giovanni La Croce, Luigi F. Da Pozzo, Jonathan Olivier, Fabio Zattoni, Matteo Facco, Fabrizio Dal Moro, Peter K.F. Chiu, Xiaobo Wu, Isabel Heidegger, Giulia Giannini, Lorenzo Bianchi, Luca Lampariello, Leonardo Quarta, Andrea Salonia, Francesco Montorsi, Alberto Briganti, Umberto Capitanio, Sigrid V. Carlsson, Andrew J. Vickers, and Giorgio Gandaglia
- Subjects
Active surveillance ,Incidental prostate cancer ,Surveillance biopsies ,Metastases ,Diseases of the genitourinary system. Urology ,RC870-923 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background and objective: Patients diagnosed with grade group (GG) 1 prostate cancer (PCa) following treatment for benign disease (“incidental” PCa) are typically managed with active surveillance (AS). It is not known how their outcomes compare with those observed in patients diagnosed with GG1 on biopsy. We aimed at determining whether long-term oncologic outcomes of AS for patients with GG1 PCa differ according to the type of diagnosis: incidental versus biopsy detected. Methods: A retrospective, multi-institutional analysis of PCa patients with GG1 on AS at eight institutions was conducted. Competing risk analyses estimated the incidence of metastases, PCa mortality, and conversion to treatment. As a secondary analysis, we estimated the risk of GG ≥2 on the first follow-up biopsy according to the type of initial diagnosis. Key findings and limitations: A total of 213 versus 1900 patients with incidental versus biopsy-diagnosed GG1 were identified. Patients with incidental cancers were followed with repeated biopsies and multiparametric magnetic resonance imaging less frequently than those diagnosed on biopsy. The 10-yr incidence of treatment was 22% for incidental cancers versus 53% for biopsy (subdistribution hazard ratio [sHR] 0.34, 95% confidence interval [CI] 0.26–0.46, p
- Published
- 2024
- Full Text
- View/download PDF